BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21914091)

  • 1. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
    Xu Y; Viswanathan HN; Ward MA; Clay B; Adams JL; Stolshek BS; Kallich JD; Fine S; Saag KG
    J Eval Clin Pract; 2013 Feb; 19(1):50-9. PubMed ID: 21914091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
    Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
    Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
    Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
    Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
    Wade SW; Satram-Hoang S; Nadkar A; Macarios D; Tosteson AN
    Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacist-provided telephonic medication therapy management in an MAPD plan.
    Ward MA; Xu Y
    Am J Manag Care; 2011 Oct; 17(10):e399-409. PubMed ID: 21999720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with osteoporosis medications.
    Solomon DH; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Brookhart MA
    Arch Intern Med; 2005 Nov; 165(20):2414-9. PubMed ID: 16287772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with biologic therapies in the Medicare coverage gap.
    Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
    Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway.
    Devold HM; Furu K; Skurtveit S; Tverdal A; Falch JA; Sogaard AJ
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):297-304. PubMed ID: 22237942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of fractures commonly associated with osteoporosis in a managed-care population.
    Christensen L; Iqbal S; Macarios D; Badamgarav E; Harley C
    J Med Econ; 2010; 13(2):302-13. PubMed ID: 20482324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a text messaging pilot program on patient medication adherence.
    Foreman KF; Stockl KM; Le LB; Fisk E; Shah SM; Lew HC; Solow BK; Curtis BS
    Clin Ther; 2012 May; 34(5):1084-91. PubMed ID: 22554973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.